肿瘤免疫疗法是当前肿瘤治疗的有效策略。天然产物作为抗癌药物的重要来源，在肿瘤免疫治疗中的作用机制仍不清楚。我们的研究通过大规模筛选增强CD8+T细胞活性的天然产物，探究其肿瘤免疫治疗作用机制。预实验结果显示伊维菌素（Ivermectin，IVM）显著促进CD8+T细胞p-S6活性。体内体外情况下，IVM显著抑制小鼠黑色素瘤的生长，并且依赖于CD8+ T细胞介导的肿瘤杀伤效应。今后我们将深入探究IVM通过影响CD8+ T细胞p-S6活性进而影响其抗肿瘤应答的作用机制？并进一步通过DARTS-MS、CRISPR/Cas9和SA-SBP-MS技术寻找IVM在CD8+ T细胞抗肿瘤应答中的作用靶点及其作用方式，通过构建体内T细胞特异性敲除其靶点小鼠模型探究IVM对其介导的抗肿瘤效应的影响。我们的研究为开发以IVM为基础的临床免疫治疗药物提供新的理论依据，并为天然产物的抗肿瘤功能研究提供新的思路。

Cancer immunotherapy is an effective strategy for current anti-cancer therapy. Natural compounds are important source of therapeutic targets for cancer drugs. The therapeutic potential and mechanism of compounds in antitumor immunity are unknown. We screened the effects of natural compounds on T cell activation through high-through screening, thereby explore the anti-tumor natural compounds. Pre-experimental results show that Ivermectin (IVM) significantly promotes the acitivity of p-S6 in CD8+ T cells. In vitro experiments showed that IVM significantly inhibited the growth of mouse melanoma and dependent on CD8+ T cell-mediated tumor killing activity. In future, we will further explore the mechanism of IVM on the antitumor response of CD8+ T cells by affecting its p-S6 activity. Furthermore, DARTS-MS, CRISPR/Cas9 and SA-SBP-MS technologies will be used to find the role of IVM in the anti-tumor response of CD8+ T cells. Our research provides new theoretical basis for the development of clinical immunotherapeutic based on IVM, and provides a new idea for the research of antitumor functions of natural compound.